Raloxifene (Evista) for breast cancer prevention in postmenopausal women

Med Lett Drugs Ther. 2006 May 8;48(1234):37.

Abstract

Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and others) for prevention of breast cancer in high-risk postmenopausal women.

Publication types

  • Comparative Study

MeSH terms

  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / prevention & control*
  • Female
  • Humans
  • Incidence
  • Neoplasm Invasiveness
  • Postmenopause*
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use

Substances

  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Raloxifene Hydrochloride